Zebin Deng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Zebin Deng has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
- Fei Deng
Department of Urology, The Second Xiangya Hospital at Central South University, Changsha, China
4 shared publications - Yinhuai Wang
Department of Urology, The Second Xiangya Hospital, Central South University, Changsha, China
4 shared publications - Jiachen Liu
The Center of Systems Biology and Data Science, School of Basic Medical Science, Central South University, Changsha, China
3 shared publications - Lizhi Zhou
Jiangxi Provincial Key Laboratory of Urinary System Diseases Department of Urology The First Affiliated Hospital Jiangxi Medical College Nanchang University Nanchang P. R. China
3 shared publications - Yingbo Dai
Department of Urology, The Fifth Affiliated Hospital of Sun Yat-Sen University, Zhuhai, Guangdong, China
3 shared publications - Hao Zhang
Department of Urology, Tianjin Institute of Urology, The second hospital of Tianjin Medical University, Tianjin, China
2 shared publications
Latest Publications
- 25 July 2025
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 37 (1) , 18-35
Keratin 20 Suppresses Exosomal Secretion of Peroxiredoxin 2 and Ferroptosis in Acute Kidney Injury
Key Points: Keratin 20 was upregulated earlier than kidney injury molecule 1 in AKI, and its proximal tubule–specific deletion aggravated kidney dysfunction in mouse models. Keratin 20 competed with apoptosis-linked gene-2-interacting protein X for peroxiredoxin 2 binding, thereby decreasing the exosomal secretion of peroxiredoxin 2 and inhibiting ferroptosis in kidney tubular cells. Background: AKI is a prevalent clinical syndrome with insufficient kidney function. Keratin 20 (KRT20), a component of intermediate filaments, is widely recognized as a biomarker of kidney tubular injury, yet its exact function in kidney disease remains uncertain. Methods: RNA sequencing data from a mouse model of ischemia/reperfusion-induced AKI were analyzed to assess KRT20 transcript levels. The effect of specific Krt20 knockout in renal proximal tubule cells ( Krt20 PTKO ) was subsequently examined in two distinct AKI mouse models. Luciferase reporter assays and chromatin immunoprecipitation–PCR was used to identify transcription factors regulating KRT20 expression, whereas immunoprecipitation followed by mass spectrometry elucidated the downstream targets of KRT20. In addition, the clinical significance of KRT20 and peroxiredoxin 2 (PRDX2) was evaluated in patients with acute tubular necrosis. Results: KRT20 was significantly upregulated in renal proximal tubule cells during the early phase of AKI, preceding the induction of kidney injury molecule 1 expression. This upregulation was mediated by FBJ Murine Osteosarcoma Viral Oncogene Homolog B in both ischemia/reperfusion and cisplatin-induced AKI models. Renal proximal tubule cell–specific knockout of Krt20 exacerbated the kidney injury during AKI. Mechanistically, KRT20 protected against AKI by sequestering PRDX2, an antioxidant protein, and inhibiting the exosomal secretion of PRDX2, eventually preventing ferroptosis in kidney tubular cells. Further analysis revealed that apoptosis-linked gene-2-interacting protein X facilitated PRDX2 exosomal release, whereas KRT20 competed with apoptosis-linked gene-2-interacting protein X for binding to the N -terminal domain of PRDX2, thereby retaining PRDX2 intracellularly. Finally, the expression levels of KRT20 and PRDX2 were correlated with kidney injury severity and kidney function decline in clinical samples. Conclusions: These findings indicate that KRT20 was upregulated in the early stages of AKI, serving to protect kidney tubule cells by sequestering PRDX2 and inhibiting ferroptosis.
- 25 July 2025
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 37 (1) , 18-35
Keratin 20 Suppresses Exosomal Secretion of Peroxiredoxin 2 and Ferroptosis in Acute Kidney Injury
Key Points: Keratin 20 was upregulated earlier than kidney injury molecule 1 in AKI, and its proximal tubule–specific deletion aggravated kidney dysfunction in mouse models. Keratin 20 competed with apoptosis-linked gene-2-interacting protein X for peroxiredoxin 2 binding, thereby decreasing the exosomal secretion of peroxiredoxin 2 and inhibiting ferroptosis in kidney tubular cells. Background: AKI is a prevalent clinical syndrome with insufficient kidney function. Keratin 20 (KRT20), a component of intermediate filaments, is widely recognized as a biomarker of kidney tubular injury, yet its exact function in kidney disease remains uncertain. Methods: RNA sequencing data from a mouse model of ischemia/reperfusion-induced AKI were analyzed to assess KRT20 transcript levels. The effect of specific Krt20 knockout in renal proximal tubule cells ( Krt20 PTKO ) was subsequently examined in two distinct AKI mouse models. Luciferase reporter assays and chromatin immunoprecipitation–PCR was used to identify transcription factors regulating KRT20 expression, whereas immunoprecipitation followed by mass spectrometry elucidated the downstream targets of KRT20. In addition, the clinical significance of KRT20 and peroxiredoxin 2 (PRDX2) was evaluated in patients with acute tubular necrosis. Results: KRT20 was significantly upregulated in renal proximal tubule cells during the early phase of AKI, preceding the induction of kidney injury molecule 1 expression. This upregulation was mediated by FBJ Murine Osteosarcoma Viral Oncogene Homolog B in both ischemia/reperfusion and cisplatin-induced AKI models. Renal proximal tubule cell–specific knockout of Krt20 exacerbated the kidney injury during AKI. Mechanistically, KRT20 protected against AKI by sequestering PRDX2, an antioxidant protein, and inhibiting the exosomal secretion of PRDX2, eventually preventing ferroptosis in kidney tubular cells. Further analysis revealed that apoptosis-linked gene-2-interacting protein X facilitated PRDX2 exosomal release, whereas KRT20 competed with apoptosis-linked gene-2-interacting protein X for binding to the N -terminal domain of PRDX2, thereby retaining PRDX2 intracellularly. Finally, the expression levels of KRT20 and PRDX2 were correlated with kidney injury severity and kidney function decline in clinical samples. Conclusions: These findings indicate that KRT20 was upregulated in the early stages of AKI, serving to protect kidney tubule cells by sequestering PRDX2 and inhibiting ferroptosis.
- 17 July 2025
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 320 (Pt 4) , 146096
Molecular characterization and functional prioritization of CD46, IL6R, KLRC1, LEAP2 and SMOX as candidate targets in acute kidney injury
- 17 July 2025
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 320 (Pt 4) , 146096
Molecular characterization and functional prioritization of CD46, IL6R, KLRC1, LEAP2 and SMOX as candidate targets in acute kidney injury
- 3 April 2024
- Published by Wiley in The FASEB Journal
- Vol. 38 (7) , e23584
PRMT4 interacts with NCOA4 to inhibit ferritinophagy in cisplatin‐induced acute kidney injury
Cisplatin‐induced acute kidney injury (AKI) is commonly seen in the clinical practice, and ferroptosis, a type of non‐apoptotic cell death, plays a pivotal role in it. Previous studies suggested that protein arginine methyltransferase 4 (PRMT4) was incorporated in various bioprocesses, but its role in renal injuries has not been investigated. Our present study showed that PRMT4 was highly expressed in renal proximal tubular cells, and it was downregulated in cisplatin‐induced AKI. Besides, genetic disruption of PRMT4 exacerbated, while its overexpression attenuated, cisplatin‐induced redox injuries in renal proximal epithelia. Mechanistically, our work showed that PRMT4 interacted with NCOA4 to inhibit ferritinophagy, a type of selective autophagy favoring lipid peroxidation to accelerate ferroptosis. Taken together, our study demonstrated that PRMT4 interacted with NCOA4 to attenuate ferroptosis in cisplatin‐induced AKI, suggesting that PRMT4 might present as a new therapeutic target for cisplatin‐related nephropathy.
- 3 April 2024
- Published by Wiley in The FASEB Journal
- Vol. 38 (7) , e23584
PRMT4 interacts with NCOA4 to inhibit ferritinophagy in cisplatin‐induced acute kidney injury
Cisplatin‐induced acute kidney injury (AKI) is commonly seen in the clinical practice, and ferroptosis, a type of non‐apoptotic cell death, plays a pivotal role in it. Previous studies suggested that protein arginine methyltransferase 4 (PRMT4) was incorporated in various bioprocesses, but its role in renal injuries has not been investigated. Our present study showed that PRMT4 was highly expressed in renal proximal tubular cells, and it was downregulated in cisplatin‐induced AKI. Besides, genetic disruption of PRMT4 exacerbated, while its overexpression attenuated, cisplatin‐induced redox injuries in renal proximal epithelia. Mechanistically, our work showed that PRMT4 interacted with NCOA4 to inhibit ferritinophagy, a type of selective autophagy favoring lipid peroxidation to accelerate ferroptosis. Taken together, our study demonstrated that PRMT4 interacted with NCOA4 to attenuate ferroptosis in cisplatin‐induced AKI, suggesting that PRMT4 might present as a new therapeutic target for cisplatin‐related nephropathy.
- Open Access
- 25 July 2023
- Published by Elsevier in Redox Biology
- Vol. 65, 102826
WBP2 restrains the lysosomal degradation of GPX4 to inhibit ferroptosis in cisplatin-induced acute kidney injury
- 25 July 2023
- Published by Elsevier in Redox Biology
- Vol. 65, 102826
Open AccessWBP2 restrains the lysosomal degradation of GPX4 to inhibit ferroptosis in cisplatin-induced acute kidney injury
- RetractedOpen Access
- 13 October 2022
- Published by Wiley in BioMed Research International
- Vol. 2022 (1) , 3667339
[Retracted] Identification of RPS7 as the Biomarker of Ferroptosis in Acute Kidney Injury
Objective. This paper aims to explore novel ferroptosis‐related biomarkers for acute kidney injury (AKI). Methods. Various bioinformatic methods, such as differential expression analysis, functional annotation analysis, machine learning, and chemical‐gene network analysis, were used in this study. Furthermore, the expression and proferroptotic role of RPS7 were validated with further bioinformatics analysis and biochemical experiments. Results. GSE30718 dataset and GSE139061 dataset were used, and the differentially expressed genes (DEGs) were screened. The DEGs were overlapped with ferroptosis‐related genes and genes associated with AKI, which led to the identification of four candidate genes. Machine learning and ROC curve analysis were conducted, and RPS7 and TRIB3 were selected for diagnostic model analysis and functional analysis. Finally, the upregulation of RSP7 in cisplatin‐induced AKI was validated in cisplatin‐induced AKI, and its proferroptotic role was confirmed in cisplatin‐treated proximal tubular cells. Conclusion. Our results indicated that RPS7 might present as a novel ferroptosis‐related biomarker for AKI, and it derived ferroptosis to accentuate cisplatin‐induced AKI.
- 13 October 2022
- Published by Wiley in BioMed Research International
- Vol. 2022 (1) , 3667339
RetractedOpen Access[Retracted] Identification of RPS7 as the Biomarker of Ferroptosis in Acute Kidney Injury
Objective. This paper aims to explore novel ferroptosis‐related biomarkers for acute kidney injury (AKI). Methods. Various bioinformatic methods, such as differential expression analysis, functional annotation analysis, machine learning, and chemical‐gene network analysis, were used in this study. Furthermore, the expression and proferroptotic role of RPS7 were validated with further bioinformatics analysis and biochemical experiments. Results. GSE30718 dataset and GSE139061 dataset were used, and the differentially expressed genes (DEGs) were screened. The DEGs were overlapped with ferroptosis‐related genes and genes associated with AKI, which led to the identification of four candidate genes. Machine learning and ROC curve analysis were conducted, and RPS7 and TRIB3 were selected for diagnostic model analysis and functional analysis. Finally, the upregulation of RSP7 in cisplatin‐induced AKI was validated in cisplatin‐induced AKI, and its proferroptotic role was confirmed in cisplatin‐treated proximal tubular cells. Conclusion. Our results indicated that RPS7 might present as a novel ferroptosis‐related biomarker for AKI, and it derived ferroptosis to accentuate cisplatin‐induced AKI.